Good news from the global health front! Researchers at the University of New Mexico (UNM) are developing a promising new Alzheimer’s vaccine—one that doesn’t target amyloid beta, the protein that has long dominated treatment strategies. Instead, this vaccine focuses on a different protein called tau.
And no, this isn’t just another lab experiment. The vaccine has already shown highly promising results in mice and primates, and now the team is preparing for the next step: human clinical trials.
What Is "Tau", and Why Does It Matter?
Before we go any further, let’s get to know "tau"—a protein that usually works quietly behind the scenes in our brains.
Tau is a natural protein with an essential role: it helps maintain the structural stability of neurons, much like scaffolding that keeps nerve cells organized and functional.
But trouble begins when "tau" undergoes a process called phosphorylation. When this process occurs excessively, tau becomes dysfunctional and gets expelled from neurons, eventually forming clumps known as tau tangles. These tangles are closely linked to Alzheimer’s disease and other neurodegenerative disorders.
Why Is "Tau" the New Target?
Several FDA-approved drugs currently focus on reducing levels of amyloid beta, another protein long suspected to cause Alzheimer’s. Unfortunately, their effectiveness has been limited. While they can reduce amyloid buildup, they haven’t proven capable of truly halting the disease’s progression.
That’s why many scientists are now turning their attention to tau as a new therapeutic target. One of the most promising breakthroughs is coming from a research team led by Dr. Kiran Bhaskar, a professor in the Department of Molecular Genetics & Microbiology at UNM School of Medicine.
A Complex Vaccine Built on Virus-Like Particle (VLP) Technology
The vaccine they’re developing uses virus-like particles (VLPs)—essentially empty shells that resemble viruses but lack any genetic material. This means they can’t replicate or cause illness, but the immune system still recognizes them as threats and produces antibodies.
In this vaccine, a specific part of the tau protein called pT181—a known biomarker for Alzheimer’s—is attached to the surface of the VLP. When injected, the body responds by producing antibodies against pT181. The hope is that these antibodies will stop or clear out the abnormal tau before it can damage the brain.
What’s more, the vaccine doesn’t require any adjuvants (additives like aluminum to boost immune response), and it only needs one primary injection followed by two boosters.
So, How Are the Results? Pretty Spectacular
The vaccine has been tested on various mouse models engineered to mimic Alzheimer’s disease, including mice with human tau genes. The outcome? Very encouraging.
The antibodies produced significantly reduced tau tangles in key brain regions—and even improved the cognitive performance of the mice. So it’s not just about clearing tau; it’s also about making the brain “smarter.”
What’s especially exciting for the scientific community is that the vaccine also triggered a strong immune response in non-human primates (macaques), whose brain and immune systems are more similar to ours. This response was long-lasting, suggesting the vaccine could offer durable protection.
All of these early results have been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, one of the leading global journals for Alzheimer’s research.
From Primates to People: Human Trials Are About to Begin
Following the promising results, Dr. Bhaskar’s team is preparing for the next milestone: a Phase 1 clinical trial in humans. The primary goal at this stage isn’t to prove effectiveness just yet, but to assess safety and tolerability. Is the vaccine safe to inject into humans? Are there any side effects?
If the vaccine passes this safety phase, it will move on to Phase 2, which will evaluate whether it can slow or even halt the progression of Alzheimer’s in human patients.
The trial will be led by Dr. Janice Knoefel from the UNM Center for Memory & Aging, which was recently designated as an official Alzheimer’s Disease Research Center by the U.S. government. Participant recruitment is scheduled to begin in early 2026, and the trial is expected to run for 12 months.
In this double-blind study, half the participants will receive the actual vaccine, while the other half will receive a placebo. Throughout the trial, researchers will monitor participants through blood tests, antibody levels, cognitive assessments, and other biomarkers.
Collaboration and Funding: The Long Road of a Vaccine
Getting to this point has required extensive collaboration. UNM partnered with UC Davis and the California National Primate Research Center for preclinical testing in primates. Vaccine production is being handled in collaboration with TheraVac Biologics, a Canadian biotech company that holds exclusive licensing rights to the technology.
Production of the vaccine must meet the FDA’s stringent Good Manufacturing Practices (GMP) standards. To support this, the team secured $1 million in funding from the Alzheimer’s Association through its Part the Cloud initiative, spearheaded by California philanthropist Michaela Hoag. Since 2012, this initiative has raised nearly $90 million to accelerate the development of Alzheimer’s therapies.
Still, the team needs more funding. Bhaskar notes that they are actively applying for additional grants in both the U.S. and Canada to cover the high costs of clinical-grade vaccine production.
So, What Does This Mean for Us?
While a fully effective Alzheimer’s vaccine is still years away, this innovation offers a promising direction. Targeting tau may prove to be a more effective strategy than focusing solely on amyloid beta—especially with a vaccine platform that’s already shown to be safe and durable.
It may take several more years before we see final clinical results, but one thing is clear: this research brings genuine hope amidst the fog of Alzheimer’s, a disease for which there is still no true cure.
